| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 14.62% | 13.56% | 13.61% | 11.52% | 16.42% | 15.10% | 44.02% | 13.55% |
| Operating Margin | -39.93% | -16.55% | -26.54% | -2.66% | 7.90% | 11.18% | -217.17% | 28.21% |
| EBITDA Margin | -38.43% | -15.45% | -25.69% | -1.83% | 8.58% | 11.98% | -184.31% | 47.34% |
| Net Margin | -40.20% | -16.81% | -26.91% | -3.26% | 5.62% | 9.61% | -194.14% | 12.46% |
| Current Ratio | 10.46 | 3.81 | 4.93 | 3.00 | 3.07 | 2.37 | 17.11 | 20.64 |
| Quick Ratio | 9.16 | 3.10 | 4.24 | 2.52 | 2.42 | 2.02 | 16.97 | 20.40 |
| Debt / Equity | — | — | — | — | — | — | — | — |
| ROE | -34.64% | -19.20% | -27.22% | -5.34% | 10.47% | 16.42% | -21.96% | 1.74% |
| ROA | -32.26% | -15.32% | -23.06% | -4.07% | 7.85% | 10.82% | -20.02% | 1.60% |
| Asset Turnover | 0.80 | 0.91 | 0.86 | 1.25 | 1.40 | 1.13 | 0.10 | 0.13 |
| Book Value / Share | 3.56 | 0.47 | 0.61 | 0.46 | 0.04 | 0.06 | 0.01 | 0.02 |
Bionexus Gene Lab Corp. operates as a biotechnology company with a focus on the research and development of genomic sequencing and analysis solutions. Its primary function is to advance personalized medicine by utilizing its genetic technologies to assist healthcare professionals in identifying and customizing treatment plans for patients based on their unique genetic profiles. Notable features of Bionexus Gene Lab Corp. include its cutting-edge laboratory facilities and a comprehensive database of genetic information, which enable it to provide accurate and efficient genomic testing services. The company plays a significant role in the healthcare and biopharmaceutical sectors, impacting areas such as precision oncology, hereditary disease prevention, and drug development. By facilitating a deeper understanding of genetic predispositions and responses, Bionexus Gene Lab Corp. is integral to the evolution of targeted therapies and personalized healthcare treatments, reflecting its importance in advancing modern medical practices.